Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 4:43 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1297–1320 of 5,276 matching trials from the live ClinicalTrials.gov search.

Filters: Gainesville, Florida Clear all

Conditions: Endocrine, Nutritional, Metabolic and Immunity Disorders
Interventions: 50 grams of whole wheat bran cereal, 100 grams of whole wheat bran cereal; Dietary Supplement
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 65 Years
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Pain, Chronic, Pain, Intractable, Pain, Back
Interventions: Nalu Neurostimulation System; Device
Lead sponsor: Nalu Medical, Inc.; Industry
Eligibility: 21 Years to 80 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 8
States / cities: Larkspur, California • Walnut Creek, California • Washington D.C., District of Columbia + 5 more

Conditions: Hypertension
Interventions: CHW Education, CHW Education and Navigation; Behavioral
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 69 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Cancer
Interventions: Endoscopic Ultrasound (EUS) for fiducial placement; Procedure
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Dysphagia, Oropharyngeal
Interventions: Videofluoroscopic Swallowing Study (VF); Diagnostic Test
Lead sponsor: University Health Network, Toronto; Other
Eligibility: 18 Years and older
Enrollment: 580 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 3
States / cities: Gainesville, Florida • Cincinnati, Ohio • Columbus, Ohio

Conditions: Lymphoma, Follicular
Interventions: Bevacizumab, Rituximab; Drug
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2013
U.S. locations: 22
States / cities: Jonesboro, Arkansas • Fort Myers, Florida • Jacksonville, Florida + 17 more

Conditions: ALS
Interventions: AMX0035; Drug
Lead sponsor: Amylyx Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Chronic Kidney Disease
Interventions: Control Food, Fiber Fortified Food; Other
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Crohn's Disease
Interventions: Certolizumab Pegol (CDP870); Biological
Lead sponsor: UCB Pharma SA; Industry
Eligibility: 18 Years and older
Enrollment: 310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2012
U.S. locations: 41
States / cities: Birmingham, Alabama • Huntsville, Alabama • Little Rock, Arkansas + 37 more

Conditions: Alzheimer Disease
Interventions: Donanemab, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 60 Years to 85 Years
Enrollment: 1,736 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 185
States / cities: Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 146 more

Conditions: Carotenoids
Interventions: Yellow Sweet Corn, White Sweet Corn; Dietary Supplement
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 90 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 2, Spinocerebellar Ataxia Type 3, Spinocerebellar Ataxia Type 6, Spinocerebellar Ataxia Type 7, Spinocerebellar Ataxia Type 8, Spinocerebellar Ataxia Type 10, RFC1 Gene Mutation, Spinocerebellar Ataxia Type 27b, Healthy Participants
Interventions: Genetic Testing, Blood Collection, Magnetic Resonance Imaging (MRI) Scan, Assessments and Questionnaires, Cerebrospinal Fluid Collection; Genetic · Other
Lead sponsor: Lauren Moore; Other
Eligibility: 6 Years and older
Enrollment: 1,400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2030
U.S. locations: 16
States / cities: Los Angeles, California • San Francisco, California • Gainesville, Florida + 12 more

Conditions: Breast Cancer
Interventions: Gemcitabine, Epirubicin, Albumin-bound Paclitaxel; Drug
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 18 Years and older · Female only
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 13
States / cities: Fort Myers, Florida • Jacksonville, Florida • Lakeland, Florida + 10 more

Conditions: Amputations for Management of Sarcoma,Trauma,or Chronic Infection
Interventions: Not listed
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 99 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Episodic Migraine
Interventions: Atogepant; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 685 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 113
States / cities: Chandler, Arizona • Phoenix, Arizona • Tucson, Arizona + 91 more

Conditions: Peripheral Artery Disease
Interventions: Metformin, Placebo; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 5
States / cities: Gainesville, Florida • Chicago, Illinois • New Orleans, Louisiana

Conditions: Diffuse Intrinsic Pontine Glioma, Recurrent Anaplastic Astrocytoma, Recurrent Glioblastoma, Recurrent Malignant Glioma, Recurrent Medulloblastoma
Interventions: Fimepinostat, Therapeutic Conventional Surgery; Drug · Procedure
Lead sponsor: Sabine Mueller, MD, PhD; Other
Eligibility: 3 Years to 39 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 18
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 15 more

Conditions: Multiple Myeloma
Interventions: First-line therapy, Second-line Multiple Myeloma treatments; Other · Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 3,011 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2024
U.S. locations: 252
States / cities: Huntsville, Alabama • Tuscaloosa, Alabama • Tucson, Arizona + 211 more

Conditions: Kidney Neoplasms
Interventions: Axitinib (AG-013736), Sorafenib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 723 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 161
States / cities: Burbank, California • Downey, California • Glendale, California + 103 more

Conditions: Pulmonary Arterial Hypertension
Interventions: inhaled prostacyclin, prostacyclin, subcutaneous and intravenous prostacyclin, oral ERA, oral PDE5 inhibitors; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: Not listed
Enrollment: 1,333 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 88
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 65 more

Conditions: Metastatic Malignant Neoplasm in the Lung, Metastatic Osteosarcoma, Osteosarcoma
Interventions: Biospecimen Collection, Computed Tomography, Questionnaire Administration, Thoracoscopy, Thoracotomy; Procedure · Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 50 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2031
U.S. locations: 220
States / cities: Birmingham, Alabama • Anchorage, Alaska • Kingman, Arizona + 142 more

Conditions: Relapsing Multiple Sclerosis
Interventions: Remibrutinib oral treatment, Ocrelizumab; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years to 70 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 45
States / cities: Scottsdale, Arizona • Irvine, California • Washington D.C., District of Columbia + 40 more

Conditions: HER2 Negative Breast Cancer
Interventions: Eribulin, Cyclophosphamide, Docetaxel; Drug
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 18 Years and older · Female only
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 15
States / cities: Fort Myers, Florida • Hollywood, Florida • Pensacola, Florida + 12 more

Conditions: Use of Prescription Medications, Pharmacogenetic Testing
Interventions: Panel-based pharmacogenetic genotyping; Diagnostic Test
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 492 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Gainesville, Florida

Search by objective public record fields.

Wheat Bioactives and Immune Function

Spinal Cord Stimulation in the Treatment of Chronic, Intractable Pain Using the Nalu™ Neurostimulation System

Improving Blood Pressure Control Among Food Insecure Hypertensive Adults

Endoscopic Ultrasound-Guided Fiducial Placement for Stereotactic Body Radiotherapy

Reference Values for Videofluoroscopic Measures of Swallowing

A Study of Rituximab and Bevacizumab in Patients With Follicular Non-Hodgkin's Lymphoma

Pharmacokinetic and Pharmacodynamic Study of AMX0035 in Patients With ALS

The Effects of Fiber Fortified Foods to the Diets of Chronic Kidney Disease Patients

A follow-on Safety Study in Subjects With Crohn's Disease Who Have Previously Been Withdrawn From the Double-blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425] Due to an Exacerbation of Crohn's Disease

A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)

Sweet Corn and Carotenoids

Natural History Study of and Genetic Modifiers in Spinocerebellar Ataxias

Neo-adjuvant Gemcitabine, Epirubicin, ABI-007 (GEA) in Locally Advanced or Inflammatory Breast Cancer

Quality of Life in Amputated Patients Based on Social Deprivation Factors

Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine

Improve PAD PERformance With METformin

Fimepinostat in Treating Brain Tumors in Children and Young Adults

Connect® MM- The Multiple Myeloma Disease Registry

Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer

Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies

Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma

Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.

Trial of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Locally Advanced HER2-Negative Breast Cancer

Trial of Preemptive Pharmacogenetics in Underserved Patients